Determination of the most effective cooling temperature for the prevention of chemotherapy‑induced alopecia

Ekwall,Eva  M.; Nygren,Lisa  M.L.; Gustafsson,Anders   O.; Sorbe,Bengt  G.

doi:10.3892/mco.2013.178

Determination of the most effective cooling temperature for the prevention of chemotherapy‑induced alopecia

Authors:
- Eva M. Ekwall
- Lisa M.L. Nygren
- Anders O. Gustafsson
- Bengt G. Sorbe
View Affiliations

Affiliations: Department of Oncology, Örebro University Hospital, Örebro SE-701 85, Sweden, Department of Biomedical Engineering, Örebro University Hospital, Örebro SE-701 85, Sweden
Published online on: September 6, 2013 https://doi.org/10.3892/mco.2013.178
Pages: 1065-1071

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Computer‑controlled scalp cooling to prevent alopecia is currently available for patients undergoing chemotherapy. Previous studies have suggested that the temperature should be <22˚C at a depth of 1‑2 mm in the scalp to prevent alopecia. However, the optimal pre‑set temperature of the coolant medium to achieve this temperature requires further investigation. A pre‑study was conducted to investigate which pre‑set coolant temperature of 3 and 8˚C was the most effective in achieving a scalp temperature of <22˚C. The temperature variations at different sites of the scalp and variations within and among the participants at baseline and during the cooling procedure were also evaluated. A randomized main study was then performed to compare the efficacy and side effects of the two temperature levels during paclitaxel/carboplatin chemotherapy. A group of 5 healthy female volunteers participated in a series of scalp temperature measurements during cooling with 3 and 8˚C of the coolant medium. In the randomized main study, a total of 47 patients were included, of whom 43 were evaluable after the first cycle. A pre‑set temperature of 3˚C tended to be the most efficient in achieving a hair follicle temperature of <22˚C. The top of the head was less responsive to scalp cooling. There were no significant differences in the prevention of alopecia between the two temperatures in the main study. However, headache and a feeling of coldness were more common in the 3˚C group. A coolant temperature of 3˚C was more effective in achieving a subcutaneous temperature of <22˚C. However, this finding was not reflected by a significant difference in the prevention of alopecia in this study, although a higher incidence of side effects was associated with a lower temperature level.

View Figures

View References

1.	Fitch MI: Psychosocial management of patients with recurrent ovarian cancer: treating the whole patient to improve quality of life. Semin Oncol Nurs. 19:40–53. 2003. View Article : Google Scholar
2.	Rosman S: Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns. 52:333–339. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, et al: Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 13:219–227. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Lemieux J, Maunsell E and Provencher L: Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 17:317–328. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Girman CJ, Hartmaier S, Roberts J, Bergfeld W and Waldstreicher J: Patient-perceived importance of negative effects of androgenetic alopecia in women. J Womens Health Gend Based Med. 8:1091–1095. 1999. View Article : Google Scholar : PubMed/NCBI
6.	Cook NF: Self-concept and cancer: understanding the nursing role. Br J Nurs. 8:318–324. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Ekwall E, Ternestedt BM and Sorbe B: Recurrence of ovarian cancer-living in limbo. Cancer Nurs. 30:270–277. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Trueb RM: Chemotherapy-induced alopecia. Curr Opin Support Palliat Care. 4:281–284. 2010. View Article : Google Scholar
9.	Tollenaar RA, Liefers GJ, Repelaer van Driel OJ and van de Velde CJ: Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. Eur J Cancer. 30A:1448–1453. 1994. View Article : Google Scholar : PubMed/NCBI
10.	Bulow J, Friberg L, Gaardsting O and Hansen M: Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man. Scand J Clin Lab Invest. 45:505–508. 1985. View Article : Google Scholar : PubMed/NCBI
11.	Gregory RP, Cooke T, Middleton J, Buchanan RB and Williams CJ: Prevention of doxorubicin-induced alopecia by scalp hypothermia: relation to degree of cooling. Br Med J (Clin Res Ed). 284:1674:1982
12.	Cooke T, Gregory RP, Middleton J and Williams C: Prevention of doxorubicin-induced alopecia. Br Med J (Clin Res Ed). 282:734–735. 1981. View Article : Google Scholar : PubMed/NCBI
13.	Grevelman EG and Breed WP: Prevention of chemo-therapy-induced hair loss by scalp cooling. Ann Oncol. 16:352–358. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Trueb RM: Chemotherapy-induced alopecia. Semin Cutan Med Surg. 28:11–14. 2009. View Article : Google Scholar
15.	Janssen FP, Rajan V, Steenbergen W, van Leeuwen GM and van Steenhoven AA: The relationship between local scalp skin temperature and cutaneous perfusion during scalp cooling. Physiol Meas. 28:829–839. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Dougherty L: Comparing methods to prevent chemotherapy-induced alopecia. Cancer Nurs Pract. 5:25–31. 2006. View Article : Google Scholar
17.	Breed WP: What is wrong with the 30-year-old practice of scalp cooling for the prevention of chemotherapy-induced hair loss? Support Care Cancer. 12:3–5. 2004.PubMed/NCBI
18.	Janssen FE, Van Leeuwen GM and Van Steenhoven AA: Modelling of temperature and perfusion during scalp cooling. Phys Med Biol. 50:4065–4073. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Massey CS: A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs. 8:121–130. 2004. View Article : Google Scholar
20.	Ridderheim M, Bjurberg M and Gustavsson A: Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer. 11:371–377. 2003.
21.	Protiere C, Evans K, Camerlo J, d’Ingrado MP, Macquart-Moulin G, Viens P, et al: Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. Support Care Cancer. 10:529–537. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Katsimbri P, Bamias A and Pavlidis N: Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer. 36:766–771. 2000. View Article : Google Scholar : PubMed/NCBI
23.	Christodoulou C, Klouvas G, Efstathiou E, Zervakis D, Papazachariou E, Plyta M and Skarlos DV: Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology. 62:97–102. 2002. View Article : Google Scholar : PubMed/NCBI
24.	van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW and Breed WP: Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol. 51:497–504. 2012.PubMed/NCBI
25.	Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N and Yardley D: Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 12:543–549. 2004.PubMed/NCBI